Dartmouth-Hitchcock Medical Center
The purposes of the research trial are to study the safety of ABY-029 and to understand how much of the drug is needed to reach head and neck squamous cell carcinomas (HNSCC) so it can be visualized best by surgeons. Investigators will do this by comparing two groups of participants that receive different, very small amounts of ABY-029. Investigators will use an imaging system during surgery to record the amount of ABY-029 in the participant's tumor and in the surrounding tissue.
Inclusion Criteria: 1. Preoperative diagnosis of head and neck squamous cell carcinoma with planned surgical resection of the oral cavity, oropharynx, larynx, or hypopharynx. 2. Tumor judged to be operable. 3. Valid informed consent by participant. 4. Age ≥ 18 years old. 5. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Patients with a medical history of (Grade 2 or higher) hepatic/renal function compromise. 2. Prisoners 3. Individuals who are pregnant or breast feeding. 4. Patients on experimental or approved anti-EGFR targeted…
ABY-029 will be administered via single intravenous injection to subjects with HNSCC approximately 1-3 hours prior to surgery. All research procedures will occur during surgery. The research procedures involve image and measurement data collection and biopsy specimen sampling. Research data collection will occur at 3 or 4 time points during surgery using either standard-of-care tools and methods or non-significant risk experimental devices. No follow-up visit will be required of participants. Participants will be monitored for possible adverse events for approximately 30 days by the operating surgeon involved in the clinical trial procedures and through review of participant medical records.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.